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(med tillstånd från förlaget) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   To individuals with odour intolerance and  
 increased airway sensitivity  
in the hope of better understanding   
of this disease in the future. 
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Airway sensory hyperreactivity linked to capsaicin sensitivity  
Definitions and epidemiology 
Åke Johansson M.D, Institute of Medicine at Sahlgrenska Academy, 
University of Gothenburg, Department of Internal Medicine. 
Abstract 
Aims:      
• To study the relationship between odour intolerance and capsaicin sensitivity 
and to develop a definition of airway sensory hyperreactivity (SHR).  
• To study epidemiology of odour intolerance; particularly regarding airway 
symptoms, and to relate odour intolerance to possible risk factors.  
• To investigate  the relationships between SHR and other respiratory diseases. 
• To study psychiatric morbidity at SHR. 
 
Material and methods: Totally 2847 adult subjects were included in these studies; 
55% of them were women and 897 were patients. Studies I and IV were performed 
among patients referred to the Allergy Centre at the Central Hospital of Skövde, 
Sweden. Study IV also included a group of asthma patients from three Care Centres. 
Study II was a cross-sectional, population-based epidemiological study of adult 
inhabitants in Skövde, and in study III randomly selected individuals from this 
population-based study were used. In all four studies, we used questionnaires to 
evaluate the symptoms arising from odour exposure, the consequences of these 
symptoms for the participants’ social lives, and smoking habits. Olfactory function 
was evaluated in study II. Patients referred to the Allergy Centre were diagnosed with 
medical history, allergy investigations, and nose and pulmonary function tests when 
appropriate. In study IV methacholine tests were performed in patients with SHR in 
order to exclude asthma. Capsaicin inhalation tests were used in study I, III and IV. 
 
Results: The limiting value for the capsaicin inhalation test was defined as 35 coughs 
after provocation with a concentration of either 0.4 or 2.0 µM capsaicin. The 
prevalence of SHR, defined as odour intolerance with affective and behavioural 
consequences and a positive capsaicin test, was estimated at 6% (95% CI: 4.2-8.4) in a 
general Swedish population. Odour intolerance with affective and behavioural 
consequences was reported by 19% (95% CI: 15-22), while one-third reported general 
odour intolerance. There was no evidence for an increased prevalence of SHR among 
asthma patients, an increased prevalence of asthma among SHR patients, any 
relationship between SHR and smoking, any relationship between SHR and depression 
or anxiety, nor any association between odour intolerance and changed sense of smell. 
 
Conclusions: The diagnosis “Airway sensory hyperreactivity” (SHR) is proposed for 
patients with airway symptoms and affective reactions to and behavioural 
consequences of odour intolerance, who also have a positive capsaicin inhalation test.  
 
Keywords: Capsaicin; chemical sensitivity; epidemiology; odour intolerance;  
sensory hyperreactivity;                     
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Definitions 
 
Chemical sensitivity 
Self-reported problems related to exposure to non-toxic concentrations of chemicals. 
The definition includes circumstances related to non-odourous exposure. See Odour 
intolerance.  
 
Odour sensitivity 
Self-reported problems related to exposure to odours and pungents. The term “Odour 
sensitivity” is often used as a synonym for Odour intolerance, but today it is 
sometimes preferred as a description of increased airway sensitivity to odours and 
pungents. 
 
Odour intolerance 
Self-reported problems related to exposure to odours and pungents. In this thesis, the 
term is used as a synonym for Odour sensitivity. It is often used as a synonym for 
Chemical sensitivity, although this is really a wider concept. 
 
Odour intolerance with self-reported affective and behavioural consequences 
Odour intolerance with self-reported affective reactions to odour exposure and 
behavioural disruptions in daily activities is defined as a score ≥43 on the Chemical 
Sensitivity Scale for Sensory Hyperreactivity (CSS-SHR). 
 
Sensory hyperreactivity (SHR) 
This term was initially used for a group of patients with odour sensitivity and airway 
symptoms after simple clinical characteristics (I). In later studies, Airway Sensory 
Hyperreactivity (SHR) was defined as the combination of odour intolerance with 
affective reactions and behavioural disruptions in daily activities (measured by CSS-
SHR score) and a pathological capsaicin inhalation test (III, IV). 
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Abbreviations 
 
AAAAI American Academy of Allergi, Asthma and Immunology   
Aδ  Nerve fiber type Aδ 
β2 beta-2 receptor 
BMI Body mass index 
C2, C5 Concentration causing two or five coughs, respectively, in response to a 
provocation 
C-fiber Nerve fibres of type C 
CI Confidence interval 
CGRP Calcitonin gene-related peptide 
COPD Chronic obstructive pulmonary disease  
CSS Chemical sensitivity scale 
CSS-SHR Chemical sensitivity scale for sensory hyperreactivity 
GINA Global Initiative for Asthma 
EEG Electroencephalogram 
ERP Event-related potential in EEG after stimulation 
FEV1 Forced expiratory volume in one second after a maximal inspiration 
HAD Hospital anxiety and depression scale 
IEI Idiopathic environmental intolerance 
NGF Nerve growth factor 
MCS Multiple chemical sensitivity 
OR Odds ratio 
PC20 Concentration causing a 20% fall compared to pre-provocation value 
PET scan Positron emission tomography imaging 
SHR Airway sensory hyperreactivity 
SP Substance P 
SOIT Scandinavian Odour-Identification Test  
TRP Transient receptor potential channel   
TRPV-1 Transient receptor potential channel – vanilloid receptor 1  
VR-1 Vanilloid receptor 1 
WHO World Health Organization 
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Introduction 
 
In their daily clinical work, physicians analyze symptoms, define diseases, and try to 
find causes. One significant challenge in this endeavour is patients with symptoms 
which after close examination still do not fit into any generally accepted diagnoses; 
this is even more troublesome for the patients who feel that their symptoms are 
misunderstood. This thesis deals with one such group of patients. 
 
Airway reactions to chemicals and odours are essential protective biological 
mechanisms against inhalation of toxic substances. However, in a certain group of 
individuals, airway symptoms and sometimes general symptoms are induced by 
exposure to concentrations of odours and irritating chemical substances such as 
perfumes, flower scents, and car exhausts, which are normally regarded as non-toxic. 
These individuals have been described as having intolerance to odours and pungent 
substances, but still do not fit into any generally accepted diagnosis, despite careful 
examinations for obstructive pulmonary disease, allergy, other immunological 
disturbancies, or cardiovascular, gastrointestinal, or neurological diseases.  
 
Historical background 
Patients with a history of chemical intolerance have been studied throughout the 
world, and a number of attempts have been made to define and explain the complexity 
of their symptoms. Failure of human adaption to changes in society and environment 
have been hypothesized to cause disease since the industrial revolution, and exposure 
to new chemicals and pungents even in low concentrations has often been in focus. 
Opinions about etiology and pathogenesis have changed from time to time. Exposure 
to toxic levels of chemicals can be harmful, and can cause structural damage and 
inflammation in the airways (1); and the capability of airborne chemicals to produce 
sensory irritation and protective reflex reactions has been carefully studied (2). Nearly 
a hundred years ago, it was found that animals pre-treated with strychnine reacted 
more strongly to sensory stimulation in upper airways than did control animals (3). 
However, questions have been raised over the evidence that prolonged increased 
airway sensitivity can be caused by exposure to levels of airborne chemicals which are 
normally regarded as non-toxic.  
 
Multiple chemical sensitivity (MCS) is one example of a proposed diagnosis; it is 
characterized by symptoms from various organs as a response to exposure to low 
concentrations of chemicals in the environment (4). The symptoms are similar to those 
described for sick building syndrome (5). There have been great difficulties in finding 
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measurable physiological parameters linked to these syndromes, and shortly after the 
publication of Cullen’s work, MCS was described by some researchers as a mental 
disorder (6). However, many patients with MCS show no sign of psychiatric 
morbidity, and no psychiatric theory or treatment has been established (7). An 
investigation of young adults reported a high prevalence of odour intolerance, but in 
contrast to expectations found no association with anxiety or depression (8). Other 
researchers have emphasized the interactions between the olfactory and trigeminal 
systems, and the possibility of learned behaviours or other cognitive or emotional 
reactions as a result of odour exposure, as possible mechanisms underlying the 
symptoms (9-11).   
 
Exposure and reactions to chemicals have attracted attention from the perspective of 
workers’ health, but the lack of scientific evidence for MCS as a toxicologically 
mediated disorder has made the use of this terminology a matter of doubt and 
discussion. Idiopathic environmental intolerance (IEI), once proposed as a diagnosis 
by Randolph in 1950, has been recommended instead of MCS because it does not 
point out the exposure as the cause of the problems. Summaries of this subject field are 
given in ´Workshop on MCS´ (12) and in ´Position statement of the AAAAI board of 
directors´ (13). As is the case for MCS, the symptoms of IEI are often regarded as 
reflecting psychological problems; e.g. after applying Bradford Hill's criteria (14-16).  
 
Other research groups have proposed diagnoses for individuals with airway symptoms 
which cannot be explained by generally accepted diseases. Löwhagen described an 
“asthma-like” functional respiratory disorder related to odour and pungent exposure 
(17). Individuals with these symptoms often have symptoms from both upper and 
lower airways, and sometimes also general symptoms, so the condition was later 
renamed functional breathing disorder (18).  
 
Another syndrome which was proposed to define these problems was hyperventilation 
syndrome, which is characterized by a variety of somatic symptoms, induced by 
physiologically inappropriate hyperventilation, and reproduced in whole or in part by 
voluntary hyperventilation. The Fourth International Symposium on Respiratory 
Psychophysiology discussed hyperventilation syndrome and attempted to settle on a 
definition, but this definition has been questioned (19). The hyperventilation test was 
found to be invalid as a test for the problems diagnosed as hyperventilation syndrome, 
and instead Howell suggested the term behavioural breathlessness (20); still, the 
dispute about the diagnosis of hyperventilation syndrome has continued (21, 22). 
Dysfunctional breathing is another example of the introduced diagnoses to describe 
patients with non-asthmatic divergent breathing patterns and breathing problems (23, 
24).   
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The descriptions of symptoms overlap, to a great extent, in the syndromes described 
above, and the lack of objectively measurable physiological findings has been 
problematic. It is not easy to assess asthma and other respiratory symptoms with 
questionnaires alone, and it is important to be aware of the need for validation of such 
tools when they are used in scientific studies (25).  
 
A study with controlled perfume provocation in odour intolerant patients showed that 
the symptoms that these patients experienced after odour exposure could be induced 
even when the subjects could not detect any smell (26). Another finding was that 
patients with odour sensitivity and airway symptoms demonstrated increased cough 
reaction to inhaled capsaicin, compared both to healthy subjects and to patients with 
asthma (27). It was also shown that it is possible to block both symptoms and cough 
response from capsaicin inhalation test with a pre-inhalation of lidocain (28). We have 
chosen to focus on patients with symptoms from the upper and lower airways related 
to odour and pungent exposure, and to develop an objective test – the capsaicin 
inhalation test – to study this field (I, III). 
 
Prevalence of odour intolerance 
Although intolerance to odours and pungent substances is a frequently reported 
problem in industrialized countries, before 1995 no one had studied its prevalence in a 
general population. A questionnaire has been developed as a research tool for 
investigating this problem, although its authors emphasized the difficulties inherent in 
using questionnaires to distinguish between asthma and chemical sensitivity (29).  
 
The prevalence of chemical sensitivity was assessed in a telephone survey conducted 
in North Carolina, where 1446 households in a rural area were selected randomly. 
Allergy was diagnosed from the questionnaire as “becoming sick from exposure to 
natural things”, and chemical sensitivity as “becoming sick after smelling chemical 
odours”. According to these definitions, 35% of respondents reported allergy and 33% 
reported some degree of chemical sensitivity. One third of those reporting symptoms 
of chemical sensitivity said that it happened at least once a week (30).  
 
In a similar telephone survey among a more urban population in Californa, in which 
more than 4000 adults participated, 16% of the respondents reported that they were 
“allergic or unusually sensitive to everyday chemicals”. In this population, 6% had 
been diagnosed by a doctor with MCS or enviromental illness; but, surprisingly, nearly 
half of them did not report any sensitivity to chemicals, and the authors could find no 
explanation for this. Furthermore, among the 11% who reported asthma, 19% reported 
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doctor-diagnosed environmental illness or MCS as compared to 4.6% in non-
asthmatics (31).  
 
Another population-based questionnaire study investigated symptoms in patients with 
asthma, allergic rhinitis, and odour intolerance. Chest tightness as well as upper and 
lower airway symptoms were common among patients with odour intolerance. 
Asthmatics reported often feeling ill from some odours and non-asthmatics from 
others. Individuals with chemical sensitivity reported often asthma and a borderline 
significance for increased chemical sensitivity among asthmatics compared to non-
asthmatics was also found (32).  
 
A later postal survey of the population in the south of Sweden showed that 10% of the 
respondents reported annoyance from the smell of chemicals and 13% annoyance from 
other smells. There were indications of a minor influence on subjective physical and 
mental well-being in the group who reported annoyance from odours (33). When 
comparing groups of individuals annoyed by smell, individuals annoyed by electricity, 
and a control group, those annoyed by electricity showed strongly elevated scores 
within the anxiety/neuroticism dimension, while those annoyed by smell had a slight 
elevation on only one anxiety scale (34). 
 
In a population study, with a random sample of more than 1000 individuals, conducted 
in the continental United States using a telephone questionnaire, 14% of the 
respondents were diagnosed with asthma and 11% reported being hypersensitivity to 
chemicals. Of those with asthma, 27% also reported being hypersensitive to chemicals 
and 7% were also diagnosed with MCS (35). 
  
The quality of these studies varies, and they raise questions regarding recruitment bias 
and the accuracy of the questionnaire-based diagnoses of allergy, asthma, and 
chemical sensitivity. In addition, none of them evaluated the possible effect on 
chemical sensitivity of changes in the sense of smell. The findings of high prevalence 
of chemical sensitivity among asthma patients in several studies are evident. However, 
the telephone survey studies often report a very high asthma prevalence; and if asthma 
is overdiagnosed, it is difficult to assess the prevalence of chemical sensitivity among 
asthmatics. In all, this points to a need for additional research. The present thesis 
addresses this need with a population-based study in which symptoms were recorded 
via a structured interview together with an assessment of the sense of smell (II), and an 
investigation of the relationship between airway sensory hyperreactivity (SHR) and 
asthma (IV). 
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Symptoms in individuals with odour intolerance   
Patients who report odour intolerance often also complain of having a stuffy nose, 
itching in the upper airways or in the ears, eye irritation, hoarseness, cough, dyspnoea, 
or a feeling of blocked airways in the larynx region. When it comes to mucosal 
reactions after exposure to perfume and other fragrance products, symptoms in the 
upper airways are more common than those in the lower airways. Sensitive individuals 
also sometimes report pressure over the chest and even chest pain accompanied by 
general symptoms like headache, perspiration, vertigo, and tiredness (18, 26, 36, 37). 
Some of these patients have been mistakenly diagnosed with asthma, e.g. those who 
report breathing trouble and chest discomfort after exercise without having either 
asthma or signs of other obstructive lung disease (38).  
 
In a five-year study of the prognosis of patients with airway odour sensitivity in 
combination with increased capsaicin sensitivity, the severity of symptoms remained 
constant and was related to low quality of life (39). 
 
Different strategies are required to allow patients with these symptoms to cope in daily 
life. The feeling of being socially handicapped is intensified by other people’s lack of 
understanding, despite the fact that sensitivity to odours and chemicals is common 
within the population. In addition, patients are often concerned that the symptoms will 
transition into a serious disease (40).  
 
In accordance with the discussion above, we chose a questionnaire that is not 
constructed to assess the symptoms, but to measure the affective reactions to and 
behavioural consequences of chemical sensitivity, CSS-SHR (41). CSS-SHR is a 
shorter version of the Chemical Sensitivity Scale (CSS) (42, 43). Since the symptoms 
in individuals with odour intolerance without allergy or asthma have been a matter of 
debate, we also included other aspects of symptomatology in the investigations (I-IV). 
  
Innervation of the airways  
The main physiological function of the upper airways is to guarantee the quality of 
inhaled air, and so mechanisms to warm and humidify the inhaled air and to protect the 
lower airways from inhaled particles and toxic substances are important. Airway 
reactions to chemical stimuli are essential protective physiological mechanisms against 
the inhalation of harmful substances. These functions require an afferent sensory 
nervous system, the common chemical sense, to register the temperature, the humidity, 
and the quality of inhaled air (44). Both the trigeminal (ophthalmic, maxillary, and 
mandibular nerve) and the glossopharyngeal nerve are involved in the afferent 
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innervations of upper airways, and the vagal nerve plays a similar role in the lower 
airways. The afferent nerves contain A-fibres (e.g. Aδ-fibres) and unmyelinated C-
fibres that branch through the basal membrane near the tight junctions between the 
epithelial cells. The protective physiological mechanisms of the airways also require 
the efferent nervous system to regulate secretion in the nose, mucosal swelling, and 
pharyngeal and laryngeal function. Irritation of mucous membranes in the nose can 
result in bronchial constriction, but it is not known whether this reflex mechanism is 
mediated through cholinergic or non-cholinergic parasympathetic systems (45, 46). 
The innervations of the airways, immunological reactions in the upper and lower parts 
of the airways, and known connections give us a basis for the concept of the united 
airway (44, 47). 
 
Together with the common chemical sense, the sense of smell plays an important role 
in the physiological system protecting us from inhalation of harmful substances. The 
sense of smell has been viewed as a low-threshold warning system, and the common 
chemical sense as a high-threshold one, but the actual situation seems to be more 
complicated. Repeated administration of n-butanol results in adaptation to smell but 
not to perception of the irritating stimulus (48). The range of thresholds for olfactory 
and trigeminal stimuli (irritants) is wide for some substances and narrow for others. 
For the majority of chemicals that have been investigated, the olfactory threshold is 
sufficiently lower than the irritant threshold to provide a warning signal before the 
onset of irritation (49). These thresholds can be studied using a method developed on 
the basis that trigeminal but not olfactory stimulus can be localized to the left or right 
side of the nasal mucosa (50). Another method is to study trigeminal threshold in 
anosmic individuals by comparison with healthy controls (9, 51). A study of anosmic 
individuals, hyposmic individuals, and healthy controls showed a lower trigeminal 
threshold in those with olfactory dysfunction than in healthy controls, and a decrease 
in trigeminal sensitivity with age (52). 
 
Research into airway sensory nervous system and sensory receptors has given new 
insights about the interactions between inhaled air and the airways, and the 
mechanisms are now better understood (53-56). A certain group of airway sensory 
receptors (TRP channels) belongs to the voltage-gated-like ion channel family. These 
receptors have, for example, the ability to sense temperature, pain, stretch, and 
osmolarity, and they seem to be important for the interaction between environment and 
respiratory system. They also have important functions in other organs. The receptors 
are built up from proteins forming tetramers with a central pore and a characteristic 
amino acid sequence that can control the flux of a specific ion (Na+, K+, Ca2+, or 
Mg2+) through the cell membrane. This function can be modified by other proteins 
(57, 58).  
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The TRPV-1 receptor (transient receptor potential channel, vanilloid receptor 1) is a 
receptor for capsaicin (59). Capsaicin is the odourless major pungent ingredient in 
chilli fruits, and belongs to a well defined group of vanillylamides (60). Inhalation of 
capsaicin causes cough in the lower airways and a hot burning sensation in the upper 
airways (61, 62) by stimulating a population of afferent neurons, most of them C-
fibers but even some Aδ-fibers (61, 63). Other receptors for capsaicin in the central 
nerve system have been postulated (64). The TRPV-1 receptor is found in nerve 
endings in the upper and lower airways, and it can even respond at temperatures of  
≥42°C, to protons (acids) and also to a series of endogenous lipids. The clinical 
importance of this receptor has yet to be evaluated, but one interesting finding is that 
mucosal injury (which is a cause of local low pH in the tissue) can lead to increased 
expression of TRPV-1 receptors. The C-fibres in the upper airways of both animals 
and humans contain neuropeptides (e.g. SP and CGRP). Neurogenic inflammation 
through axon reflexes with the release of neuropeptides has been demonstrated in both 
upper and lower airways in rodents (65), but it is questionable whether this occurs in 
the lower airway in humans and there is only a little evidence for it in the upper airway 
(66). However, the secretion of nerve growth factor (NGF) in the nose increases after 
capsaicin provocation of lower airways in patients with airway odour sensitivity. It is 
not yet known whether this is caused by a reflex mechanism or a direct effect of 
capsaicin on the nose cavity (67).  
 
The response to capsaicin in the airways can be blocked both by lidocaine (68) and by 
capsazepine. Capsazepine is a synthetic analogue of capsaicin, and acts as a 
competitive antagonist (69). In guinea pigs, the specific TPRV-1 inhibitor, V112220, a 
pyridazinylpiperazine analogue, significantly inhibits the number of coughs induced 
by both citric acid and capsaicin compared to controls (70).  
  
        Capsaicin              Capsazepine 
 
The TRP families represent a complex system of receptors in the airways, and it is an 
interesting finding that some patients with symptoms from upper and lower airways 
after exposure to odours and pungents have increased response to the capsaicin 
inhalation test. This  could be the result of increased expression of TRPV-1 or a 
closely linked protein and this is the reason for the development of a capsaicin 
inhalation test for diagnostic purposes (I, III). 
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Objective verification of odour intolerance 
Over the years, there has been much dispute about the pathophysiology of chemical 
sensitivity, but only a few provocation studies have been performed. In a systematic 
review of 37 studies regarding chemical intolerance (71), only six were blinded, and 
one of these was of chronic fatigue syndrome, which is of limited interest for 
investigation of odour intolerance with airway symptoms. Four of the blinded studies 
showed some positive results. In one of them, MCS patients underwent airway 
provocation with the chemicals that they had reported symptoms from. The 
participants could sometimes identify the stimuli, but the symptoms could not be 
reproduced when the provocations were double-blinded (72). However, in another 
study, subjects with MCS who were provoked single-blinded showed no difference 
regarding sensations of smell or development of CNS-related symptoms compared to a 
control group, but had significantly higher subjective rating of symptoms related to 
irritation (i.e., eyes, nose, throat, skin, and breathing difficulties) (73). In another study 
subjects with chemical sensitivities took longer than controls to adapt to baseline in the 
protocols of some physiological measurements. After adaptation, cases displayed 
statistically significant responses in tonic electrodermal response to test substances, 
both compared with controls and compared with the control substance. Symptoms 
were also higher in cases than in controls for body wash solution and dryer sheets (74). 
In two other studies, subjects with odour sensitivity were provoked with perfume in 
the lower airways or the eyes; they showed symptoms even when the nose was 
blocked so they could not sense smell during the experiments. These findings suggest 
a hyperreactivity of the respiratory tract induced by a trigeminal reflex via the airways 
or the eyes (26, 75).  
 
The conclusion in the review of Das-Munshi et al. was that people with MCS do react 
to chemical challenges, but that these responses occur only when they can discern 
differences between active and sham substances; this suggests that the mechanism of 
action is not specific to the chemical itself, but might be related to expectations and 
prior beliefs. However, these conclusions must be viewed with an understanding of the 
heterogeneity of the patients included in the MCS syndrome, and may not be relevant 
for all patients, as several studies concerned individuals with symptoms other than 
those from the airways. Some of the studies do not support the idea of a connection 
between the symptoms of odour sensitive patients and olfactory stimulation related to 
expectations and prior beliefs, but until now too few patients have been studied. The 
present thesis focuses on the group with mainly airway symptoms after exposure to 
odours and pungents (I-IV). 
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Development of the capsaicin inhalation test  
The finding that individuals with odour sensitivity had increased sensitivity to 
capsaicin inhalation (27) motivated the development of a capsaicin inhalation test for 
diagnostic purposes (I, III). 
 
Different provocation tests for the airways have been developed in order to study 
cough reactions in different airway diseases, and to test various cough medications. 
Capsaicin and citric acid have often been used to induce experimental and pathologic 
cough response in humans, but citric acid seems to give more problems with the 
performance of the test and the reproducibility of the results (76, 77).  
 
Capsaicin produces a dose dependent cough response after inhalation of incremental 
concentrations with no tachyphylaxis, or only a partial and temporary one. The 
response is an effect of stimulation of both the larynx and more peripheral airways (61, 
68, 77, 78). After capsaicin inhalation, patients with odour sensitivity experience 
dyspnoea, upper airway symptoms, and eye irritation (28). Inhaled lidocaine blocks 
not only the cough (68, 77, 79), but also the dyspnoea and other airway symptoms 
induced by capsaicin in patients with odour sensitivity (28).  
 
Provocation tests with inhaled capsaicin can be performed with different protocols, 
either to define the threshold concentration for coughing two or five times (C2 and C5, 
respectively), or to measure the cough response after inhalation of a fixed 
concentration (68, 77, 78, 80). Both methods have advantages and limitations. The 
fixed concentration method and the C5 threshold method both have good short-term 
reproducibility when used in appropriate populations, but a carry-over effect is seen 
after provocation with a high concentration if the tests are performed in a randomized 
order (77, 81). Long-term reproducibility has also been studied, and has been found 
sufficient for both methods (39, 81). It is important to realize that these methods do not 
measure exactly the same physiological effect. Both methods measure the response 
after the sensory signals have passed the filter in the brain and given the efferent signal 
to cough; however, the threshold method measures the threshold for coughing while 
the fixed concentration method measures the total response of cough after an 
inhalation of a concentration above the threshold. Individuals with increased airway 
sensitivity often cough even after inhalation of saline, which is a serious drawback of 
the threshold method in this patient group (27, 82). The inhalation equipment is 
important for the results, and normative data must be analyzed for the method in use 
(83).  
 
A safety investigation covering 20 years of clinical experiences of provocation tests 
with inhaled capsaicin showed no serious adverse event in humans (84). 
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Given the known sensitive cough reflex in some patients with odour intolerance, the 
threshold method did not seem to be appropriate for SHR-patients. Therefore, in order 
to develop normative data for a capsaicin inhalation test in patients with odour 
intolerance, we chose the fixed concentration method (I, III). 
 
Capsaicin sensitivity– relationship to other diseases, smoking, and gender 
Atopic patients who suffer from airway symptoms after exposure to odours and 
pungents have increased sensitivity to inhaled capsaicin compared to atopic patients 
without airway symptoms after exposure to odours (85). In asthmatics with birch 
pollen allergy, sensitivity to capsaicin increases during pollen season (86). However, 
atopic patients without asthma did not have increased capsaicin sensitivity (87), nor 
was there a correlation between cough threshold and the methacholine test; this 
suggests that cough sensitivity and bronchial responsiveness may be independently 
potentiated by different mechanisms in chronic airway inflammation (88). Another 
study of patients referred to an allergy clinic because of lower airway symptoms 
showed no relationship between capsaicin test and methacholine test (89). On the other 
hand, increased capsaicin sensitivity was found to be an important contributor to the 
presence of cough in both asthma and chronic obstructive pulmonary disease (COPD). 
No relationship between capsaicin responsiveness and airflow limitation was found, 
and therefore the mechanisms behind coughing are likely to be different from those 
causing airway obstruction, at least in patients with COPD (90). The findings 
regarding augmented capsaicin sensitivity in asthma patients were claimed to be due to 
cough variant asthma in a subgroup of the patients, since asthmatics without cough did 
not show such an increase (91).  
 
Sensitivity to inhaled capsaicin is augmented in a number of chronic pulmonary 
conditions with cough as a major symptom; for example, lower airway conditions such 
as COPD (90, 92) and cystic fibrosis (93), and also cryptogenic fibrosing 
alveolitis/idiopathic pulmonary fibrosis (94, 95). Airway sensitivity to inhaled 
capsaicin increases during respiratory infections (96), but is lower among smokers 
than among non-smokers (97, 98); the second of these findings is consistent with the 
hypothesis that nicotine inhibits or blocks the C-fibres of the sensory nervous system 
of the lower respiratory tract (99). 
   
Cough sensitivity is higher in females than in males (100, 101). Other parameters such 
as height, weight and lung function have been shown to have no major influence on 
the outcome of capsaicin provocations, and hence the disparity between males and 
females may be regarded as due to a true sex difference (102).  
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However, one study of a group of patients with chronic cough showed no gender 
differences in capsaicin sensitivity (80).  
 
Given this evidence for relationships between capsaicin sensitivity and gender and 
smoking, we were motivated to study these factors in relation to odour sensitivity (II -
IV). In addition, the disparity of opinions about the relationship between capsaicin 
sensitivity and asthma confirmed the importance of elucidating the relationship 
between SHR and asthma (IV). 
 
 
 
 
Aims of the thesis 
 
The general aims were:  
 
• to study the relationship between odour intolerance and capsaicin sensitivity 
and to develop a definition SHR.  
• to study epidemiology of odour intolerance; particularly regarding airway 
symptoms, and to relate odour intolerance to possible risk factors.  
• to investigate the relationships between SHR and other respiratory diseases. 
• to study psychiatric morbidity at SHR. 
 
Study I 
The aim of study I was to establish the capsaicin inhalation test in patients with 
pronounced odour intolerance, in comparison to healthy individuals and patients with 
other airway symptoms. 
 
Study II 
The main aim of study II was to determine the prevalence of self-reported general 
odour intolerance, and the prevalence of such sensitivity that has affective and 
behavioural consequences for the individual. Other aims were to determine the type 
and severity of the symptoms induced by odorous/pungent substances; to relate odour 
intolerance to possible risk factors such as sense of smell, gender, and smoking habits; 
and to obtain normative data for the CSS-SHR. 
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Study III 
The aim of study III was to determine the relationship between self-reported odour 
intolerance and capsaicin sensitivity, and to estimate the prevalence of SHR, defined 
as a combination of odour intolerance with affective and behavioural consequences 
and a pathological capsaicin test. A secondary aim was to evaluate, whether the order 
of administrated capsaicin had any effect on the response. 
 
Study IV 
The primary aim of study IV was to clarify whether there is a relationship between 
SHR and asthma, and to study the influence of smoking. The secondary aim was to 
study whether SHR patients show signs of increased psychiatric morbidity. 
 
 
 
 
Subjects and Methods  
 
Subjects 
The studies included a total of 2847 adult individuals, 897 of whom were patients. Of 
these, 2252 eventually participated. Women were slightly overrepresented (55%). 
Studies I and IV were performed among patients referred to the Allergy Centre at the 
Central Hospital of Skövde. Study IV also included a group of asthma patients from 
three Care Centres. Study II was a cross-sectional, population-based epidemiological 
study of adult inhabitants in Skövde, and in study III randomly selected individuals 
from this population-based study were further investigated.  
 
Ethical aspects 
Informed consent was obtained from all participants. All studies were approved by the 
Regional Ethical Review Board of Gothenburg, Sweden; Dnr L 147-99 (I), Dnr Ö 452-
00 (II), Dnr Ö 616-02 (III), Dnr 239-06 (IV). 
 
Questionnaires 
Questionnaires were used to evaluate the symptoms and their consequences for the 
participants’ social lives (I-IV). In study I, we evaluated sensitivity to the odours of 
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chemical substances such as perfumes, cleaning agents, flower scents, tobacco smoke, 
and car exhaust fumes; we also evaluated the social effects of sensitivity to odorous 
substances. In later studies we used the CSS-SHR, a validated questionnaire on the 
affective and behavioural consequences of odour sensitivity (41) (II-IV). In study IV 
we also included the Hospital Anxiety and Depression Scale (HAD), a validated 
instrument for investigating signs of depression and anxiety in patients (103-105), and 
made use of a questionnaire for classifying asthma severity into four groups by 
symptoms and medication, in accordance with the GINA guidelines (106). 
 
Capsaicin inhalation test 
A nebulizer (Pariboy 36; Paulritzau Pari-werk KG; Starnberg-am-See, Germany) was 
used to administer inhalation of aqueous dilutions of an odourless capsaicin solution 
prepared from a stock solution of capsaicin. The number of coughs was registered and 
counted for 10 min from the start of provocation. The test was initiated with the 
inhalation of l ml of saline for 6 min, in order to teach the inhalation technique to the 
participants. This was followed by 4 min of rest, and then the individuals were 
provoked in the same manner with doses of capsaicin (0.4, 2.0, and 10.0 µM). The 
10.0 µM capsaicin solution was later excluded due to experiences of excessive 
coughing and interrupted provocations on this concentration (III, IV). The cut-off for a 
positive capsaicin inhalation test, primarily defined in study I and further discussed in 
study III, was finally defined as 35 coughs after provocation with a concentration of 
either 0.4 or 2.0 µM capsaicin. The exclusion criteria for the capsaicin provocation test 
were pregnancy and breast-feeding, and the provocation was not administered during 
an acute respiratory infection nor for the following three weeks. 
 
Methacholine test  
The methacholine test was performed as described by Löwhagen (107). Methacholine 
chloride solution was nebulised in a nebulizer (Pariboy, output 0.8ml/min with 
continuous nebulisation) and inhaled by tidal breathing for 2 min. Methacholine was 
inhaled in doubling concentrations starting with 0.03 mg/ml to a maximum 
concentration of 16 mg/ml. FEV1 was measured 30 and 90 s after each inhalation. The 
provocation was continued with 5 min intervals between inhalations until a fall in 
FEV1 of 20% or greater was obtained; and the concentration of methacholine 
producing such a fall in FEV1 (PC20) was recorded. Treatment with inhaled β2-agonists 
was ceased 6 h prior to challenge for short-acting β2-agonists and 24 h prior to 
challenge for long-acting. A fall in FEV1 of ≥20% after inhalation of a concentration 
of ≤4.0 mg/ml was regarded as a positive test (IV).  
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Results  
 
Development of the capsaicin inhalation test for SHR 
 
Patients with upper and lower airway problems who had been admitted for allergy 
testing (n=95) were grouped into those with SHR symptoms (n=15, 16%) and those 
without, and compared with healthy controls. All individuals reacted dose-dependently 
to the capsaicin inhalation test, and patients who scored high on the odour intolerance 
questionnaire reacted more than other patients and also more than healthy controls. 
The 95% confidence intervals for mean values of cough response after 2.0 and 10.0 
µM did not overlap between patients and controls, and the limit values were thereafter 
set to 10, 35, and 55 coughs respectively (I). The cut-off for a positive capsaicin 
inhalation test was finally defined as 35 coughs after provocation with a concentration 
of either 0.4 or 2.0 µM capsaicin (III, IV).   
 
Participants with a positive CSS-SHR score (≥43) coughed more on average than 
others on the capsaicin concentrations of 0.4 µM (p <0.01) and 2.0 µM (p <0.0001). 
The order of inhaled capsaicin concentration was found to influence the results, and 
hence inhalation with increasing doses was recommended (III).  
 
The capsaicin inhalation test was performed in a total of 345 individuals without any 
major adverse event. 
 
SHR was defined as a combination of odour intolerance with affective reactions to and 
behavioural consequences of exposure (CSS-SHR ≥43) and a pathological capsaicin 
inhalation test (III).  
 
Epidemiology 
 
The prevalence of intolerance to odorous and pungent substances in a general Swedish 
population was estimated with a structured interview including 1900 adults, 73% of 
whom completed the study (II). Self-reported odour intolerance was found in 33% of 
the participants, and was more common in women (OR=2.0, 95% CI: 1.6-2.5), but no 
increased risk was found related to age, smoking, or impaired sense of smell 
(measured with the Scandinavian Odour-Identification Test). Respiratory symptoms 
and current smoking were more common among patients with odour intolerance, but 
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were not related to either the total amount of smoking (pack-years) or BMI. The 
pattern of different types of symptoms showed that half of the 33% with self-reported 
odour intolerance reported light symptoms and the other half moderate or severe 
symptoms. More symptoms were reported from the upper than from the lower airways, 
and one-third of those complaining of odour intolerance reported other symptoms, 
such as headache and nausea (II, part 1). Odour intolerance with positive CSS-SHR 
was reported by 19% (95% CI: 15-22%) of 595 individuals. This was more common in 
women (OR=2.3, 95% CI: 1.5-3.6), but no increased risk was found in relation to age, 
smoking, or impaired sense of smell (II, part 2).  
  
Study III demonstrated a relationship between capsaicin sensitivity and CSS-SHR 
score; 81% of those with a positive capsaicin inhalation test had a positive CSS-SHR 
score, and only 5% of those with a negative CSS-SHR score had a positive capsaicin 
inhalation test. The prevalence of SHR in a general Swedish adult population was 
estimated at 6% (III). 
 
 
 
 
Fig. A positive capsaicin inhalation test was strongly related to odour 
intolerance, but a small group of individuals had a positive capsaicin inhalation 
test without a positive CSS-SHR score. In the great majority of people with 
odour intolerance, capsaicin sensitivity was normal (II- III). 
 
 
In the group of patients referred to the Allergy Centre because of airway symptoms, 
SHR (diagnosed with a positive symptom score and positive capsaicin test) was related 
to female gender, rhinitis, and lower airway sensitivity to cold air; but not to age, 
asthma, or smoking (I).  
Individuals with  
odour intolerance 
General population Individuals with a 
positive CSS-SHR 
Individuals with a  
positive capsaicin test 
SHR 
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In 724 consecutive patients referred to the Allergy Centre, the prevalence of SHR was 
investigated in four subgroups. The prevalence among asthma patients was 6.4% (95% 
CI: 2.2-10.6) and that among patients with other airway symptoms was 8.8% (95% CI: 
4.2-13.4). A lower prevalence was seen in the other two groups; “allergic rhinitis 
without asthma”, and “no airway disease” (IV). 
 
Asthma was no more common among patients with SHR than would be expected in 
the Swedish population (108-111), and there was no evidence that SHR is more 
common among asthma patients than in the general population (IV).  
 
No relationship between SHR and smoking was found, but current smokers were 
uncommon in the study population (IV).  
 
No relationship between SHR and depression was found, neither an augmented 
prevalence of  “possible depression”, according to the HAD scale, compared with data 
from general Swedish population (112). Similarly, we found no signs of increased 
“possible anxiety or depression” (according to the HAD scale) in SHR compared to 
asthmatics and other patients with a positive CSS-SHR-score, who had been referred 
to the Allergy Centre (IV). 
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Discussion 
 
The recognition of a group of patients whose symptoms are not in accordance with any 
general accepted diagnosis is a significant challenge, both in clinical practice and in 
research. In the early phase of these studies, the lack of validated tools in this area of 
research was indeed problematic. Problems in the attempts to define a disease are not 
uncommon in medical science. One example is the development of the diagnosis of 
bronchial asthma; after a decade of progress in diagnostics and treatment, the 
diagnosis has again been questioned (113, 114). The development of scientific 
knowledge was described in 1935 by Ludwig Fleck in the monograph ´Entstehung und 
Entwicklung einer wissenschaflichen Tatsache. Einfőhrung in die lehre von Denkstiel 
und Denkkollektiv´(115, 116). This work had almost been forgotten, when in 1962 
Thomas Kuhn referred to it as “an essay that anticipates many of my own  ideas”. 
Kuhn’s analysis of changes in science in the monograph ´The Structure of Scientific 
Revolutions´ obtained wide recognition, and the term “paradigm” for Fleck´s term 
“Denkstiel” has often been used (117). Fleck was trained in medicine, and his ideas 
can easily be applied to medical research. The development of the Wasserman 
reaction, with small steps being taken in interaction between several research groups 
and re-evaluation of findings in the light of new knowledge (115, 116), has indeed 
some similarity to the ongoing research into odour intolerance and the description of 
airway sensory hyperreacitivity. It is not possible to use validated methods at the 
beginning of a research project of this type, but with increasing knowledge the 
validation improves, and sometimes new interpretations of results are necessary. Often 
this can be done within the same paradigm (Denkstiel). To be accepted as a paradigm, 
a theory must explain the facts better than the competing thories, even if it does not 
explain all known facts (117). The proposed diagnoses of dysfunctional breathing for 
patients with otherwise undiagnosed breathing problems, and MCS or IEI for 
individuals with chemical sensitivity, have neither been generally accepted nor been 
replaced by other diagnoses. There is still no generally accepted paradigm which 
explains the disease in these patients.  
 
In this thesis, we have focused on a group of individuals who experience airway 
symptoms and sometimes general symptoms after exposure to concentrations of 
odours and irritating chemical substances which are normally regarded as non-toxic. 
Most of these individuals regard themselves as suffering from a disease; however, the 
symptoms may be a reaction to a society overloaded with different fragranced 
products, and could be seen simply as one extreme of normal variability. These 
symptoms have often been explained as a supposedly augmented psychiatric 
vulnerability (6, 14, 15). However, the findings that symptoms could be induced by 
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single-blinded perfume provocation, the increased sensitivity to capsaicin in the 
airways in a group of such individuals, and the blockage of both symptoms and cough 
response of capsaicin inhalation after double-blinded lidocain inhalation, strengthens 
the hypothesis of another pathophysiology (26-28, 75, 118). 
 
We started by establishing limit values for a capsaicin inhalation test in patients with 
airway odour intolerance in comparison to control subjects (I). This knowledge was 
used to develop the CSS-SHR questionnaire, which was aimed at evaluating the 
affective reactions to and behavioural consequences of the symptoms instead of trying 
to measure the symptoms themselves (41). This is important since sensitive individuals 
may change their behaviour due to the symptoms. Some individuals with increased 
sensitivity may avoid exposure, and hence do not suffer from symptoms, while others 
may choose to take part in social life even at the cost of exposure and consequent 
symptoms. In the population-based study, a relationship was established between CSS-
SHR score and capsaicin response. With the use of the capsaicin test and CSS-SHR, 
we were able to distinguish a group of individuals characterized by a validated 
questionnaire and a measurable physiological finding. For this group, we propose the 
diagnosis of SHR (III).  
 
Although SHR has measurable characteristics, there are still unsolved problems. For 
example, 20% of individuals with a positive capsaicin inhalation test do not have a 
positive CSS-SHR score. This result can be interpreted in different ways. One possible 
explanation is that the questionnaire has a low sensitivity; however, this does not seem 
likely in the light of the fact that 19% of the population have a positive CSS-SHR 
score. If the questionnaire has enough sensitivity, then there must be other 
explanations. It may be that capsaicin sensitivity is linked to odour intolerance without 
a direct causal connection, or it may be a matter of the timetable for the development 
of this syndrome; the increased capsaicin sensitivity may develop before any 
symptoms are experienced, or sometimes the opposite may be the case. It is also 
important to remember that cough sensitivity to capsaicin may be augmented in other 
lower airway conditions, such as COPD (90, 92), cystic fibrosis (93), and idiopathic 
pulmonary fibrosis (94, 95). 
 
Another question is how to explain the odour intolerance in individuals without a 
positive capsaicin inhalation test. As many as two-thirds of individuals with odour 
intolerance and a positive CSS-SHR score belong to this group (III). This result may 
be partially explained by the fact that the cut-off for pathologic capsaicin inhalation 
test was set with the aim of achieving high specificity, which resulted in a lower 
sensitivity. It is also important to remember that upper airway symptoms are more 
common than lower airway symptoms among individuals with odour intolerance, and 
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our present test system actually tests sensitivity in the lower airways. We also think 
that the group which reports odour intolerance is a heterogenic group, and so different 
mechanisms may be involved. Many of these individuals have no airway symptoms, 
but instead report more general problems such as headache and nausea. The CSS-SHR 
is not focused on airway symptoms, and it may have both advantages, regarding 
coping strategies (discussed elsewhere), and disadvantages, in its nonspecificity. Even 
if chemical sensitivity can be found in anosmic individuals, the complex interaction 
between the olfactory and the trigeminal system may be of importance (10). Our 
strong memory of odours, often connected to positive or negative experiences, gives a 
plausible background for psychological reactions.  
 
New findings may change the general opinion of a disease, and recent research 
regarding airway sensory receptors gives us a new view of the situation. In recent 
years there has been an increasing interest in the family of TRP ion channels, which 
are able to sense conditions including temperature, noxious stimuli, stretch, 
osmolarity, and pain, and which may be involved in different diseases via an increased 
level of channel expression (58, 119, 120). The TRP ion channels are important for 
multiple organ systems in their interaction with the environment. Patients with chronic 
cough showed a significant correlation between cough response to capsaicin and the 
number of TRPV-1 positive nerves in airway mucosa (121), and the expression of 
TRPV1 is also upregulated in the smooth muscle of the airways in these patients (122). 
The complexity of the TRP receptor system may explain why so many individuals 
with odour intolerance have a negative capsaicin test and why some with a positive 
capsaicin test do not have symptoms; however, it is also possible that other 
mechanisms are involved.  
 
The psycho-neurological processing of chemosensory information varies between 
individuals, and mechanisms other than variations in the receptor system may of 
course be important for the development of symptoms (123). In a recently published 
study of mice, an interaction was found between exposure to odorous sulphur-
containing substances and the response to capsaicin with increased response to 
capsaicin after exposure to the odours. This interaction may be one explanation for the 
findings of a connection between odour intolerance and increased capsaicin sensitivity 
(III) (124). If this can be reproduced in humans, it could help to explain the 
pathophysiological basis for odour intolerance and SHR. Another recent study tested 
the hypothesis of an association between capsaicin cough sensitivity and sensitivity to 
CO2 with respect to detection sensitivity and electrophysiological brain response. The 
results imply that capsaicin cough sensitivity, such as in SHR, is related to a higher 
detection sensitivity, and tends to be related to faster cortical processing of other 
chemosomatosensory substances, at least of CO2 (125).  
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PET scan has been used as a method of visualizing dynamic changes in metabolism. A 
study of regional cerebral blood flow with PET scan showed that individuals with 
MCS process odours differently from controls; however, this occurs without signs of 
neuronal sensitization. One possible explanation for the observed pattern of activation 
in MCS is a top-down regulation of odour-response via the cingulate cortex (126). 
This finding is difficult to interpret, as it could result from either psychological 
reactions or changes in the airway sensory system in this patient group.  
 
Some studies report that chemical sensitivity is linked to psychiatric morbidity  (6, 14), 
and several studies have demonstrated a relationships between asthma and anxiety or 
depression (127-129). The SHR patients in study IV did not show augmented 
prevalence of “possible depression” (according to the HAD scale) compared with data 
from the general Swedish population (112). Sign of increased prevalence of “possible 
anxiety or depression” (according to the HAD scale) in SHR were not shown, when 
we, in the Allergy Centre population, compared patients with SHR to patients with 
asthma and other diagnoses with a positive CSS-SHR score, or compared to what was 
earlier found in an adult asthma population (128). The results do not support the theory 
that psychiatric morbidity is a major cause of SHR. However, the number of patients 
was limited; further studies in this field are needed.  Our results cannot unreservedly 
be generalised to other groups of patients with chemical sensitivity, for example those 
with MCS. 
  
Our results could indeed be interpreted as changes in the psycho-neurological 
processing of the afferent stimuli from the airways after certain exposure; but the few 
provocation studies in SHR patients, the correlations between symptom score and 
response in the capsaicin test, the finding of changes in response regarding nerve 
growth factor in nasal lavage fluid after capsaicin test in SHR patients, the lack of 
signs of psychiatric morbidity in SHR patients, and our general experience of the 
patients, all speak in favour of the proposed diagnosis of SHR and of a peripheral 
somatic pathophysiology for this disease (I, III, IV) (26, 67, 75).  
 
Odour intolerance is a common problem, and our results regarding the prevalence of 
odour intolerance in a general Swedish population are in accordance with those of 
other studies (30-33, 130). Like others, we found that odour intolerance is more 
common in females (II, III) (30-33, 130). There is no obvious explanation for this. In 
study III, one-third of the individuals with positive CSS-SHR had a positive capsaicin 
inhalation test, both among men and among women. This result could support the idea 
that there is a direct linkage between odour intolerance and capsaicin sensitivity which 
is not correlated with sex differences. 
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Chemical sensitivity seems to be increased in at least some groups of asthma patients 
(32, 35, 37), and capsaicin sensitivity is also more common in asthma patients (91); 
however, we found no evidence for SHR being more prevalent in asthmatic patients 
than in the general population (IV). Our results cannot rule out the theory that SHR is 
more common in asthmatics, but there is no obvious relationship, and our results do 
support the idea that SHR has a different pathogenesis than asthma. On the other hand, 
since both conditions are common, there ought to be several patients with both asthma 
and SHR. This interaction may result in diagnostic difficulties and a risk of 
overmedication of symptoms in asthma patients.     
 
A study of the prevalence of SHR in teenagers showed considerably lower prevalences 
of odour intolerance, positive CSS-SHR scores, and SHR (1%) than in adults (131). 
These findings indicate that SHR is an acquired disorder. It must be asked whether 
exposure to odours and pungent substances causes this disease, or whether it merely 
induces the symptoms. Toxic effects and gene-environment interactions are indeed 
important to consider as possible causes of the disease. As is the case with MCS, SHR 
patients are likely to regard themselves as having been injured by the particular 
exposure that accompanied the onset of problems. Today, we have no definite 
knowledge regarding such connections, and this is important to remember, when we 
are answering insurance questions.    
  
With our definition of SHR, we have described a disorder with a validated 
questionnaire and a measurable physiological test. This definition cannot include all 
patients with odour intolerance or chemical sensitivity, nor can it include all patients 
with MCS, IEI, or dysfunctional breathing, even though a proportion of patients with 
MCS have a positive capsaicin test (132). Our present definition of SHR is chosen to 
give high specificity, which will result in few false positives but probably more false 
negatives. This is important to remember, not only when it is used as a research tool, 
but also when it is used in clinical practice. The development of the Wasserman 
reaction to a medical success is now history. Other methods are in use, and the 
Wasserman reaction is regarded to have too low a specificity for today’s standards. 
The asthma diagnosis is questioned, although the progress in that field has resulted in 
the development of good treatment for most cases. This thesis is concerned with a new 
field of research, and our methods will undoubtedly be replaced by others with higher 
sensitivity and specificity; still, we have taken what we hope are only the first steps 
towards a better understanding of patients with odour intolerance. 
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Conclusions 
Intolerance to odours is a common phenomenon in the Swedish population, and there 
is a considerable group of individuals in which airway odour sensitivity is linked to an 
increased capsaicin cough sensitivity. This is more common among women than 
among men. A high score on a questionnaire measuring the affective and behavioural 
consequences of odour intolerance, in combination with a positive capsaicin inhalation 
cough test, represents a distinct clinical entity. For this group of individuals, we 
propose the diagnosis of airway sensory hyperreactivity (SHR). The capsaicin 
inhalation test was developed in several steps, to establish normative data and cut-off 
values.  
 
SHR was no more common in asthmatic patients than in the general population, and 
asthma was no more common in SHR patients than in the general population. The 
number of patients included in our study was small, and the results must be interpreted 
with caution. Although the symptoms of SHR and asthma are often confused, there is 
no obvious connection between the two conditions. We have not found evidence for 
the hypotheses that SHR is related to sense of smell or smoking habits, nor for the 
theory of psychiatric morbidity as a major cause of this disease. 
 
 
 
Perspectives for the future 
Controlled provocation studies with various irritating substances are needed to 
increase our understanding of the nature of this type of reactions. A strict definition of 
the patient group is essential for interpretation of provocation tests and comparison 
with controls. Methods developed to distinguish olfactory and trigeminal responses 
could help us understand the mechanisms behind the results of the provocations. 
Studies of EEG-related responses in the cortex (event related potentials, or ERPs) after 
sensory stimulation of the upper airway are promising in this field.  
 
Investigation of the airway sensory receptors (e.g. the capsaicin receptor TRPV-1) has 
given new insights into the interface between inhaled air and the airways, and further 
studies in this field could be a key to the underlying pathophysiology of SHR. The 
capsaicin inhalation test may be useful in these studies. More knowledge of 
pathophysiology and pathogenesis will increase the possibility of finding methods for 
prevention and treatment of the disease. 
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Summary in Swedish –  
Populärvetenskaplig sammanfattning 
 
 
Vid exponering för dofter och luftburna kemiska ämnen uppstår hos somliga personer 
symtom som t.ex. tungandning, tryck eller tyngdkänsla över bröstet, hosta, 
slembildning, heshet, snuva, nästäppa och ögonirritation. Svettningar, trötthet, yrsel 
och huvudvärk rapporteras också. Denna till synes ökade känslighet för doftande 
ämnen och kemikalier leder inte sällan till problem både i arbetsliv och på fritid. Vid 
utredning finner man ofta varken allergi, astma eller annan känd sjukdom. Läkemedel 
mot astma och allergi har inte heller någon effekt. Detta tillstånd har bl.a. benämnts 
multipel kemisk överkänslighet (multiple chemical sensitivity, MCS) och funktionell 
andningsrubbning. Innan man 1998 påvisade en stark koppling mellan sådana 
symptom och en ökad känslighet i luftvägarna för inandad capsaicinlösning saknades 
sätt att mäta någon störning i kroppsfunktionerna hos dessa personer. Capsaicin är det 
starka men luktfria kryddämnet i spansk peppar. Det kan tillredas i exakt angivna 
spädningar för testning. Det har emellertid funnits ett behov av gränsvärden för 
capsaicintest vid undersökning av denna patientgrupp.  
 
Avhandlingen har som syfte att bestämma gränsvärden för capsaicintest, att definiera 
begreppet sensorisk hyperreaktivitet i luftvägar (SHR) utifrån symtom samt känslighet 
vid capsaicintest och att beskriva förekomsten av dessa problem i befolkningen. 
Slutligen skall sambanden mellan SHR, luktsinne, tobaksrökning och astma 
undersökas samt betydelsen av förekomst av ångest- och depressionsbenägenhet för 
SHR belysas. Som grund för detta har 4 delarbeten genomförts. Dessa har efter 
prövning godkänts av regionala etikprövningsnämnden i Göteborg.     
 
Syftet för studie I var att etablera gränsvärden för capsaicintest hos patienter med 
luftvägsbesvär utlösta av dofter och kemikalier. 95 patienter, som remitterats för 
allergiutredning undersöktes genom provokationer med inhalation av capsaicin i 
stigande koncentrationer. Antalet hoststötar registrerades, relaterades till 
luftvägssymptom och patienter med och utan doftkänslighet jämfördes med en grupp 
friska individer. Hos alla försökspersonerna uppstod en dosberoende reaktion i form av 
hosta vid inhalation av stigande koncentration capsaicin. Gränsvärden för ökad 
känslighet vid capsaicintest bestämdes till 10, 35 respektive 55 hoststötar vid 
koncentrationsstegen 0.4, 2.0 och 10 µM capsaicin. De uppsatta gränsvärdena för 
capsaicinkänslighet analyserades vidare och kunde förenklas till ett värde. Om man 
reagerar med ≥35 hoststötar efter inhalation av 1 ml 0.4 eller 2.0 µM capsaicinlösning 
har man en ökad känslighet och testet bedöms som en positiv capsaicintest.  
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I studie II undersöktes förekomsten av självrapporterad känslighet för dofter och 
kemikalier, vidare förekomsten av sådan känslighet som medförde att personernas 
beteende påverkades. Dessutom studerades om rökvanor eller förändrat luktsinne har 
betydelse. Av ett slumpmässigt urval av 1900 vuxna invånare i Skövde från olika 
åldersgrupper angav 33% viss doftkänslighet medan 19% hade doftkänslighet av sådan 
grad att detta påverkade personerna emotionellt och socialt. Förekomsten var dubbelt 
så hög hos kvinnor som hos män men förändrat luktsinne eller rökvanor tycks inte 
påverka förekomst av doftkänslighet.   
 
I studie III påvisades att det fanns starka samband mellan doftkänslighet och 
känslighet för capsaicin. 6% av befolkningen hade doftkänslighet av sådan grad att 
detta påverkade personerna emotionellt och socialt kombinerat med en ökad känslighet 
för capsaicin. Vår slutsats blev att denna grupp representerade en egen sjukdomstyp 
som fick namnet sensorisk hyperreaktivitet i luftvägarna (SHR). 
 
I studie IV undersöktes sambanden mellan SHR och astma. Dessutom undersöktes 
betydelsen av rökning och benägenhet för oro och ångest för förekomsten av SHR. 
Astma och SHR tycks vara helt skilda sjukdomar och rökning tycks inte öka risken för 
SHR. Oro, ångest och depression är vanligt vid alla kroniska sjukdomar, även vid 
luftvägssjukdomar, men SHR tycks inte vara speciellt kopplat till psykisk ohälsa vid 
jämförelse med allergi- och astmapatienter. 
 
Slutsatsen blir att doftkänslighet är vanligt i den svenska befolkningen. En grupp av 
dessa personer med påvisbar ökad känslighet i luftvägar, mätbar med capsaicintest, 
kan avgränsas och deras sjukdom kan definieras som SHR. Denna sjukdom tycks inte 
ha något samband med astma och inte heller med förändrat luktsinne eller rökning. 
Luftvägssjukdomar medför ofta en psykisk påfrestning och med hänsyn till detta kan 
inte något speciellt samband mellan SHR och psykisk ohälsa påvisas.  
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